Abstract
Lung cancer is the main cause of cancer-related death worldwide and non-small-cell lung cancer (NSCLC) represent 84% of the cases. The oncogene KRAS and the subsequent activation of the MAPK pathway is a main contributor to lung cancer progression. ERK3, or MAPK6, is an atypical MAPK with a poorly understood signaling pathway but highly expressed in lung cancer. Our aim is to study the expression of ERK3 in NSCLC and to understand if and how it may contribute to lung cancer progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
